Hosted on MSN23h
Gilead’s lenacapavir applications for HIV gain EMA validation
Gilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...
Here are highlights from Tuesday’s Analyst Blog:
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
BLUE Stock Plunges on Update
It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus. Recap of the Week’s ...
Trump’s Funding Cuts Halt Rollout Of HIV Prevention Drug
A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...
Zacks.com on MSN5h
Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA
It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and ...